Cosmo Intelligent Medical Devices

Cosmo IMD develops cutting-edge Intelligent Medical Devices to empower physicians and improve patients’ lives.   Visit our website to learn how we are pioneering human-AI collaboration. www.cosmoimd.com #cosmoimd #gigenius #ai #artificialintelligence #aihealthcare #medicaldevices #medtech #colorectalcancer #colonoscopy #endoscopy

Cosmo Pharmaceuticals Reports Stellar Half-Year 2024 Results: I am delighted to share that Cosmo Pharmaceuticals has delivered outstanding half-year results for 2024. Our commitment to innovation and excellence continues to drive remarkable achievements. Here are some key highlights: Financial Performance: - **Revenue:** Reached an impressive €136.2 million, reflecting the strong market demand for our advanced pharmaceutical solutions. - **EBITDA:** Achieved a robust €94.2 million, underscoring our operational efficiency. - **Operating Profit:** Recorded at €87.0 million, showcasing our profitability. - **Net Cash Inflow:** Generated a significant €99.2 million from operating activities. - **Dividend:** Paid a €2.00 per share dividend for FY2023, rewarding our shareholders. Health Tech: - **GI Genius™ Expansion:** Our AI-enhanced endoscopy system continues to grow, with the new ColonPRO™ version approved by the FDA in January. This software incorporates an enhanced algorithm, significantly improving detection capabilities and automating physician workflows. **Dermatology Success:** - **Winlevi® Dominance:** Continues to be the #1 prescribed topical acne product in the U.S. The global expansion is on track with successful launches in Canada and Australia. Submissions for approval are ongoing in 14 additional countries, promising further growth. **Gastroenterology Growth:** - **Increased Shipments:** Our GI products have seen a surge in shipments to partners, reflecting our expanding market presence. **CDMO Growth:** - **Revenue Increase:** Our contract development and manufacturing organization (CDMO) division grew by 9.3%, driven by higher orders from existing customers. **Pipeline & Regulatory Highlights:** - **New Submissions:** GI Genius™ module 300 powered by Nvidia IGX has been submitted to the FDA for clearance. - **Clinical Trials:** Progressing well with key trials, including the Androgenetic Alopecia phase III trial and Distal Ulcerative Colitis phase II study. - **Global Approvals:** Lumeblue® New Drug Application approved in China, with our partner CMS preparing for the launch. These achievements underscore our relentless pursuit of quality and innovation, driving forward our mission to enhance healthcare outcomes worldwide. I am immensely proud of our team’s dedication and excited about the future prospects. Thank you to our incredible team, partners, and shareholders for your unwavering support. Together, we are shaping a brighter future at Cosmo Pharmaceuticals! https://lnkd.in/eFy54vUJ Cosmo Pharmaceuticals Andrea Cherubini Nhan Ngo Dinh Hazel Winchester #EarningsResults #Pharmaceuticals #Innovation #Healthcare #Growth #CosmoPharmaceuticals #TeamSuccess

Cosmo Pharmaceuticals Reports Stellar Half-Year 2024 Results: I am delighted to share that Cosmo Pharmaceuticals has delivered outstanding half-year results for 2024. Our commitment to innovation and excellence continues to drive remarkable achievements. Here are some key highlights: Financial Performance: - **Revenue:** Reached an impressive €136.2 million, reflecting the strong market demand for our advanced pharmaceutical solutions. - **EBITDA:** Achieved a robust €94.2 million, underscoring our operational efficiency. - **Operating Profit:** Recorded at €87.0 million, showcasing our profitability. - **Net Cash Inflow:** Generated a significant €99.2 million from operating activities. - **Dividend:** Paid a €2.00 per share dividend for FY2023, rewarding our shareholders. Health Tech: - **GI Genius™ Expansion:** Our AI-enhanced endoscopy system continues to grow, with the new ColonPRO™ version approved by the FDA in January. This software incorporates an enhanced algorithm, significantly improving detection capabilities and automating physician workflows. **Dermatology Success:** - **Winlevi® Dominance:** Continues to be the #1 prescribed topical acne product in the U.S. The global expansion is on track with successful launches in Canada and Australia. Submissions for approval are ongoing in 14 additional countries, promising further growth. **Gastroenterology Growth:** - **Increased Shipments:** Our GI products have seen a surge in shipments to partners, reflecting our expanding market presence. **CDMO Growth:** - **Revenue Increase:** Our contract development and manufacturing organization (CDMO) division grew by 9.3%, driven by higher orders from existing customers. **Pipeline & Regulatory Highlights:** - **New Submissions:** GI Genius™ module 300 powered by Nvidia IGX has been submitted to the FDA for clearance. - **Clinical Trials:** Progressing well with key trials, including the Androgenetic Alopecia phase III trial and Distal Ulcerative Colitis phase II study. - **Global Approvals:** Lumeblue® New Drug Application approved in China, with our partner CMS preparing for the launch. These achievements underscore our relentless pursuit of quality and innovation, driving forward our mission to enhance healthcare outcomes worldwide. I am immensely proud of our team’s dedication and excited about the future prospects. Thank you to our incredible team, partners, and shareholders for your unwavering support. Together, we are shaping a brighter future at Cosmo Pharmaceuticals! https://lnkd.in/eFy54vUJ Cosmo Pharmaceuticals Andrea Cherubini Nhan Ngo Dinh Hazel Winchester #EarningsResults #Pharmaceuticals #Innovation #Healthcare #Growth #CosmoPharmaceuticals #TeamSuccess

How Cosmo Pharmaceuticals cranked up the cancer-catching AI behind Medtronic’s GI Genius ColonPro: Cosmo Intelligent Medical Devices President Nhan Ngo Dinh and Science, AI and Data SVP Andrea Cherubini discuss how their team developed advanced machine learning algorithms for improved polyp detection and neural network for new features, the challenges they overcame and the technology advances that made it all possible. My first of three posts from this interview is live now at Medical Design & Outsourcing: https://lnkd.in/gw67sEj3

🌟 **Exciting Visit from Kimberly Powell at Cosmo Pharmaceuticals!** 🌟 This morning, we had the incredible honor of hosting Kimberly Powell Healthcare GM and VP for NVIDIA at our Cosmo Pharmaceuticals offices in Lainate. From the pictures, you can see the intensity and enthusiasm that filled the room as we delved into deep discussions about our current capabilities and explored future opportunities to strengthen our partnership. Our conversation spanned across various fronts, particularly focusing on the immense potential in the AI space beyond Gi Genius. We explored how #AI can revolutionize not just pharma but also enhance our manufacturing processes at Cosmo. This visit marks a significant step forward in our collaboration with Nvidia, and we are excited about the innovative paths we are paving together. The future looks incredibly promising, and we are eager to see the groundbreaking advancements that will emerge from this partnership. A big thank you to Kimberly Powell for her visit and inspiring insights. Here’s to pushing the boundaries of healthcare and technology together! 🚀 #AI #HealthcareInnovation #Partnership #Pharma #CosmoPharmaceuticals #Nvidia #FutureForward

#OpenData democratizes progress and innovation! Hot off the press: happy to announce that our REAL-Colon dataset paper has been published in Springer Nature Group Scientific Data journal! Cosmo Intelligent Medical Devices is on a mission to advance #AI in #healthcare, ignite innovation in #medicaldevices, and strengthen our bonds with the #scientific community. With this dataset, we’re: - Empowering researchers in regions where accessing high-quality data is tough - Catalyzing AI breakthroughs in gastrointestinal health - Showcasing our dedication to transparency and collaboration Kudos to the team for the incredible work: Carlo Biffi, Giulio Antonelli, Sebastian Bernhofer, Cesare Hassan, Daizen Hirata, Mineo Iwatate, Andreas Maieron, Antonella Melina, Michela Ruperti, Pietro Salvagnini, Nhan Ngo Dinh and the entire Cosmo Intelligent Medical Devices team. AI enthusiasts, download the dataset and join us in making a lasting impact on healthcare! Check the paper at the link: https://lnkd.in/dTRU2GZF #AI #HealthcareInnovation #OpenData #CosmoIMD #ScientificImpact #AIResearch #NatureScientificData

🎉 We are thrilled to 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 𝗚𝗶𝗼𝘃𝗮𝗻𝗻𝗶 𝗗𝗶 𝗡𝗮𝗽𝗼𝗹𝗶 𝗮𝘀 𝗼𝘂𝗿 𝗻𝗲𝘄 𝗖𝗘𝗢! 🎉 and 🌟 𝗛𝗲𝗮𝗿𝘁𝗳𝗲𝗹𝘁 𝗧𝗵𝗮𝗻𝗸𝘀 𝘁𝗼 𝗔𝗹𝗲𝘀𝘀𝗮𝗻𝗱𝗿𝗼 𝗗𝗲𝗹𝗹𝗮 𝗖𝗵𝗮̀ 🌟 With an impressive track record and a visionary approach, Giovanni is set to lead us into an incredible new chapter of innovation and success.   𝗚𝗶𝗼𝘃𝗮𝗻𝗻𝗶 𝗗𝗶 𝗡𝗮𝗽𝗼𝗹𝗶 brings over 20 years of extensive experience in the Life Sciences industry, demonstrating exceptional leadership in both entrepreneurial ventures and corporate environments. As a visionary leader, Giovanni Di Napoli has been at the forefront of integrating artificial intelligence into the GI field, earning recognition from Forbes Magazine for their innovative contributions. With a strong commitment to diversity and inclusion, Giovanni Di Napoli has consistently surpassed corporate standards, achieving a 42.4% diverse representation within his teams. His dedication to advancing patient health and raising awareness of critical health issues, such as colon and esophageal cancer, through collaborations with leading organizations, reflects his deep sense of social responsibility. We are confident that under Giovanni Di Napoli's leadership, our company will continue to innovate and excel, driving forward our mission to improve people’s lives by developing innovative drugs and products that address significant unmet medical needs and health outcomes worldwide.   We extend our deepest gratitude to 𝗔𝗹𝗲𝘀𝘀𝗮𝗻𝗱𝗿𝗼 𝗗𝗲𝗹𝗹𝗮 𝗖𝗵𝗮̀  for his exceptional leadership and unwavering dedication. 🙏 His vision and commitment have been the cornerstone of our success, and we are excited to continue on this journey together. Thank you for everything you've done and for everything yet to come! 🌟   Join us in giving a warm welcome and stay tuned for the amazing journey ahead! 🚀   #Welcome #ThankYou #Leadership #Gratitude #NewChapter #Cosmo #wearecosmo #Innovation #NewBeginnings #ExcitingTimes 

Introducing ColonPRO™ software — the latest upgrade for the GI Genius™ intelligent endoscopy module. See ColonPRO™ in action at #DDW2024 at Booth 3229. Learn more: https://ow.ly/LBfW50RuRSc GI Genius is intended as an adjunct to colonoscopies and does not perform any diagnosis. See important risk information: https://ow.ly/h9Yg50RuRSe #Endoscopy #Healthcare #sponsored

Introducing ColonPRO™, our latest software update for Gl Genius™ intelligent endoscopy module developed with Cosmo Intelligent Medical Devices, and our strategic collaboration with ModMed are paving the way for endoscopic care and pushes the boundaries of what's possible. Read the press release: https://bit.ly/4aMlsAC #Medtronic #Healthcare #GICare #AllnHealthcare

🚀 New on the Scope Forward Show! Dive into the fascinating world of AI in gastroenterology with Andrea Cherubini, PhD, Senior Vice President for Science, AI, and Data at Cosmo Intelligent Medical Devices, Medtronic's partner behind GI Genius. Andrea's insights offer a unique window into the future of medicine, where AI not only supports but enhances medical expertise. Specifically, he shares how GI startups and enterprises can take advantage of the GI Genius platform by developing and launching their own apps. Highlights: ▶ The Genesis of GI Genius: Andrea Cherubini shares the inception story of Cosmo IMD's collaboration with Medtronic in developing GI Genius, emphasizing the 'perfect storm' of opportunities that led to this revolutionary AI tool in gastroenterology. ▶ Human-AI Hybrid Teams in #Healthcare: Andrea articulates how #human-AI collaborations enhance the accuracy and effectiveness of medical diagnoses, surpassing the capabilities of human or AI working in isolation. ▶ Navigating the AI Landscape in #Gastroenterology: Andrea elaborates on the challenges and potential of AI, advocating for responsible and innovative integration of these technologies in healthcare settings. This conversation is not just an exploration of AI's current state in healthcare but a glimpse into a future where AI and human expertise collectively redefine what's possible in medicine. Thank you once again Andrea Cherubini for your pioneering work in #gastroenterology. #scopeforward #ai #digitalGI #endoscopy